AR and breast cancer: Therefore, both AR+/hi LNCaP-CRPC and AR–/lo LAPC9-CRPC models [33] are characterized by reduced luminal cell signature (as expected) but increased basal cell (BC), stem cell (SC), MES and neural signatures (Figure 3A–E; left).